Current stock page

Catalysts

PCVX Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

PCVXVaxcyte, Inc.

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$63.37−$1.32 (−2.04%)

Latest quote

  • Momentum
    81
  • Value
    —
  • Quality
    54
  • Risk resilience
    53
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 23, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 66/100

Momentum 81/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 29.26%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 81/100AIQ Edge 10/10 Sector Leader
Beat rate
38%
3 of 8 reported periods
Average surprise
-7.3%
Across covered historical reports
Latest result
+5.7%
Nov 4, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 4, 2026—-$2.11-$1.99+5.7%$12.5M—
Aug 5, 2026—-$2.06-$1.97+4.4%$12.5M—
May 6, 2026—-$1.78-$2.30-29.4%$12.5M—
Feb 24, 2026—-$1.53-$1.80-17.7%$18.75M—
Nov 4, 2025—-$1.27-$1.56-22.8%——
Aug 6, 2025—-$1.12-$1.22-8.9%——
May 7, 2025—-$1.02-$1.04-2.0%——
Feb 25, 2025—-$1.16-$1.02+12.1%——

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
10
Buy
1
Hold
12-month analyst target
$122.33
+93.05% versus current price
Based on 11 analyst observations. Targets are estimates, not predictions.
Low target
$120.00
+89.36% vs latest price
Average target
$122.33
+93.05% vs latest price
High target
$125.00
+97.25% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 23, 2027

Next known earnings or reporting date.

EPS estimate-$1.92

Current analyst expectation for the upcoming report.

Revenue estimate$12.5M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score81

Where event reaction would show up first.

AIQ score66/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
11
Average target
$122.33
Target upside
93.05%
Target range
$120.00 - $125.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
4
Neutral
1
Negative
0
seekingalpha.com · Oct 19, 2026

Vaxcyte: Vaccine Titan In The Making (NASDAQ:PCVX)

Vaxcyte is a late clinical-stage vaccine company positioned as a potential disruptor in the vaccine market. Learn more about PCVX stock here.

rttnews.com · Oct 16, 2026

Show Me The Money: Vaxcyte Delivers 100%+ Gains As Pneumococcal Vaccine Program Advances

2026 has been a breakout year for Vaxcyte Inc. (PCVX), with a string of positive pipeline developments lending its shares fresh momentum. With multiple clinical readouts on the horizon, the company's 2027 calendar could prove pivotal for its pneumococcal vaccine ambitions.

gurufocus.com · Oct 12, 2026

PCVX Reiterated by Cantor Fitzgerald -- Price Target Announced at $120

Vaxcyte Inc (PCVX) Analyst Rating Update On October 12, 2026, analyst Carter Gould from Cantor Fitzgerald reiterated the rating for Vaxcyte (PCVX) as Overwei

insidermonkey.com · Sep 17, 2026

Vaxcyte (PCVX) Brings In Pharma Veterans As Its Big Test Nears

On September 3, Vaxcyte (NASDAQ:PCVX) announced two new C-suite hires and moved up the date for its most important looming catalyst.

finance.yahoo.com · Sep 8, 2026

Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing

Guggenhime surrendered shares to cover tax withholding on vesting RSUs, retaining about 164,000 shares valued at $10.12 million.

Open full news and sentiment

PCVX Catalysts FAQ

What are the next catalysts for PCVX stock?

PCVX's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move PCVX stock?

Upcoming events that could move PCVX include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could PCVX's next earnings report affect the stock?

PCVX's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive PCVX stock higher?

PCVX could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt PCVX stock?

PCVX could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.